We are Main Street
U.S.

Liquidia Settled Patent Lawsuits for $380.7 Million

The settlement requires Liquidia to pay hundreds of millions and narrow its YUTREPIA drug label.

Updated on Oct. 14, 2026 in Healthcare

Bold flat-color editorial illustration of an architectural balance structure, depicting a corporate legal settlement and pharmaceutical labeling adjustment.
Liquidia settled six patent and antitrust lawsuits with United Therapeutics for $380.7 million, requiring the narrowing of its YUTREPIA drug label. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies prioritize settling patent litigation to maintain patient access to medications?

Liquidia has reached a $380.7 million settlement to end six patent and antitrust lawsuits with United Therapeutics. The agreement follows a September federal court ruling finding patent infringement and requires Liquidia to remove specific indications from its YUTREPIA drug label.

Why it matters

The deal resolves significant legal uncertainty and removes a major barrier for Liquidia by curbing ongoing litigation costs. The company must now manage liquidity to cover the heavy payout while shifting its commercial focus for YUTREPIA.

Liquidia agreed to pay $380.7 million in total, including an initial $175 million payment due within 30 business days. This follows the company's third-quarter net product sales of $222.7 million for YUTREPIA.

The players

Liquidia

A biopharmaceutical company focused on developing and commercializing therapeutic products, including the inhaled drug YUTREPIA.

United Therapeutics

A biotechnology company focused on the development of products for patients with chronic and life-threatening diseases, specifically pulmonary arterial hypertension.

The details

Under the terms of the settlement, Liquidia will make two additional $72.7 million installments in 2027 and a separate $60.3 million payment related to antitrust litigation. To comply with the agreement, the company has submitted a supplement to remove the PH-ILD indication from the YUTREPIA label and terminated its promotional agreement for Treprostinil Injection. Management expects to fund these obligations through a combination of current cash reserves and ongoing product sales.

Timeline

  1. September 30, 2026: A Delaware federal court ruled that Liquidia infringed on patents.

  2. October 14, 2026: Liquidia announced the global settlement agreement.

  3. January 31, 2027: Liquidia is scheduled to pay the first $72.7 million installment.

  4. April 30, 2027: Liquidia is scheduled to pay the second $72.7 million installment.

Market Landscape

This settlement follows a September 30 ruling in a Delaware federal court that identified patent infringement by Liquidia. The agreement effectively ends six separate legal actions between the two companies, allowing both firms to move past a period of sustained patent and antitrust litigation.

Operators should monitor upcoming payment dates to track the company's cash flow impact through 2027. Management must also account for reduced product reach now that the PH-ILD indication has been removed from the YUTREPIA label.

The takeaway

Large-scale litigation settlements require precise cash management and often demand immediate operational changes to product labeling. Leaders should track these legal milestones to understand how they restrict future product positioning and capital allocation.

Further reading

For more on industry regulatory and legal shifts, visit the Healthcare section.

Live Poll

Should pharmaceutical companies prioritize settling patent litigation to maintain patient access to medications?